Mini-quiz: Pharmacotherapy for Alcohol Dependence

Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.

How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.

Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.

Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.

How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.

Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.

Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.

Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.